Malaysia
· Delayed Price · Currency is MYR Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.31 billion. The enterprise value is 1.55 billion.
| Market Cap | 1.31B |
| Enterprise Value | 1.55B |
Important Dates
The last earnings date was Friday, May 16, 2025.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | Mar 5, 2025 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 71.67% |
| Float | 450.08M |
Valuation Ratios
The trailing PE ratio is 17.92 and the forward PE ratio is 13.99. KLSE:DPHARMA's PEG ratio is 0.72.
| PE Ratio | 17.92 |
| Forward PE | 13.99 |
| PS Ratio | 1.48 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.96 |
| P/FCF Ratio | 14.95 |
| P/OCF Ratio | 11.45 |
| PEG Ratio | 0.72 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.09, with an EV/FCF ratio of 17.75.
| EV / Earnings | 21.27 |
| EV / Sales | 1.76 |
| EV / EBITDA | 10.09 |
| EV / EBIT | 13.69 |
| EV / FCF | 17.75 |
Financial Position
The company has a current ratio of 3.83, with a Debt / Equity ratio of 0.71.
| Current Ratio | 3.83 |
| Quick Ratio | 2.60 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 3.27 |
| Debt / FCF | 5.75 |
| Interest Coverage | 4.52 |
Financial Efficiency
Return on equity (ROE) is 10.48% and return on invested capital (ROIC) is 5.84%.
| Return on Equity (ROE) | 10.48% |
| Return on Assets (ROA) | 5.22% |
| Return on Invested Capital (ROIC) | 5.84% |
| Return on Capital Employed (ROCE) | 9.42% |
| Revenue Per Employee | 451,438 |
| Profits Per Employee | 37,306 |
| Employee Count | 1,957 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.31 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 20.65 million in taxes.
| Income Tax | 20.65M |
| Effective Tax Rate | 22.05% |
Stock Price Statistics
The stock price has increased by +10.40% in the last 52 weeks. The beta is 0.83, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +10.40% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 57.87 |
| Average Volume (20 Days) | 1,451,380 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 883.47 million and earned 73.01 million in profits. Earnings per share was 0.08.
| Revenue | 883.47M |
| Gross Profit | 320.56M |
| Operating Income | 113.41M |
| Pretax Income | 93.66M |
| Net Income | 73.01M |
| EBITDA | 150.41M |
| EBIT | 113.41M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 258.85 million in cash and 503.41 million in debt, giving a net cash position of -244.56 million or -0.25 per share.
| Cash & Cash Equivalents | 258.85M |
| Total Debt | 503.41M |
| Net Cash | -244.56M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | 711.75M |
| Book Value Per Share | 0.74 |
| Working Capital | 561.75M |
Cash Flow
In the last 12 months, operating cash flow was 114.27 million and capital expenditures -26.77 million, giving a free cash flow of 87.50 million.
| Operating Cash Flow | 114.27M |
| Capital Expenditures | -26.77M |
| Free Cash Flow | 87.50M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 36.28%, with operating and profit margins of 12.84% and 8.26%.
| Gross Margin | 36.28% |
| Operating Margin | 12.84% |
| Pretax Margin | 10.60% |
| Profit Margin | 8.26% |
| EBITDA Margin | 17.02% |
| EBIT Margin | 12.84% |
| FCF Margin | 9.90% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.17%.
| Dividend Per Share | 0.03 |
| Dividend Yield | 2.17% |
| Dividend Growth (YoY) | 30.43% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 39.53% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 5.58% |
| FCF Yield | 6.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.78 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.78 |
| Piotroski F-Score | 6 |